Copyright
©The Author(s) 2022.
World J Clin Cases. Aug 16, 2022; 10(23): 8170-8185
Published online Aug 16, 2022. doi: 10.12998/wjcc.v10.i23.8170
Published online Aug 16, 2022. doi: 10.12998/wjcc.v10.i23.8170
Table 3 Analysis of the total duration of hospitalization and intensive care unit stay against the age group
| Variables | Age group (yr) | Group A (famotidine) | Group B (control) | ||||||
| 1-10 d | 11-20 d | 21-30 d | > 31 d | 1-10 d | 11-20 d | 21-30 d | > 31 d | ||
| Duration of hospital stay, group A (n = 104), group B (n = 104) | 11-20 | 1 | 1 | 0 | 0 | 4 | 0 | 0 | 0 |
| 21-30 | 1 | 1 | 0 | 0 | 8 | 8 | 0 | 0 | |
| 31-40 | 4 | 5 | 0 | 0 | 12 | 8 | 0 | 0 | |
| 41-50 | 7 | 8 | 1 | 0 | 4 | 8 | 4 | 0 | |
| 51-60 | 18 | 11 | 5 | 0 | 0 | 17 | 5 | 2 | |
| 61-70 | 11 | 10 | 4 | 0 | 12 | 4 | 4 | 0 | |
| 71-80 | 6 | 6 | 0 | 0 | 0 | 4 | 0 | 0 | |
| > 81 | 3 | 1 | 0 | 0 | 4 | 0 | 0 | 0 | |
| Total (%) | 51 (49) | 43 (41.5) | 10 (9.5) | 0 (0) | 40 (38.5) | 49 (47.1) | 13 (12.5) | 2 (1.9) | |
| Duration of ICU stay, group A (n = 104), group B (n = 104) | 11-20 | 2 | 0 | 0 | 0 | 4 | 0 | 0 | 0 |
| 21-30 | 2 | 0 | 0 | 0 | 12 | 4 | 0 | 0 | |
| 31-40 | 6 | 3 | 0 | 0 | 20 | 0 | 0 | 0 | |
| 41-50 | 8 | 8 | 0 | 0 | 12 | 0 | 4 | 0 | |
| 51-60 | 23 | 10 | 1 | 0 | 8 | 13 | 1 | 2 | |
| 61-70 | 17 | 6 | 2 | 0 | 12 | 4 | 4 | 0 | |
| 71-80 | 9 | 3 | 0 | 0 | 0 | 4 | 0 | 0 | |
| > 81 | 4 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | |
| Total (%) | 71 (68) | 30 (29) | 3 (3) | 0 (0) | 68 (65.4) | 25 (24) | 9 (8.6) | 2 (1.9) | |
- Citation: Mohiuddin Chowdhury ATM, Kamal A, Abbas MKU, Karim MR, Ali MA, Talukder S, Hamidullah Mehedi HM, Hassan H, Shahin AH, Li Y, He S. Role of H2 receptor blocker famotidine over the clinical recovery of COVID-19 patients: A randomized controlled trial. World J Clin Cases 2022; 10(23): 8170-8185
- URL: https://www.wjgnet.com/2307-8960/full/v10/i23/8170.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i23.8170